Preliminary clinical data from patients with advanced melanoma indicate that combining DC therapy with CTLA-4-targeting monoclonal antibodies enhances therapeutic efficacy compared to monotherapy [95,96]. This evidence concerns the gene CTLA4 and melanoma.